Please note that this summary was posted more than 5 years ago. More recent research findings may have been published.
This is a plain English summary of an original research article. The views expressed are those of the author(s) and reviewer(s) at the time of publication.
The statin, rosuvastatin, taken by adults before and after heart surgery, did not prevent atrial fibrillation or heart muscle injury compared to placebo. Acute kidney injury was more common for adults who received rosuvastatin.
Atrial fibrillation (AF) is a type of irregular heart rhythm which is relatively common after heart surgery. A previous review of published research suggested that atrial fibrillation might be half as common with perioperative atorvastatin therapy, but the evidence was not reliable.
This large trial included 1,922 adults from a hospital in Hong Kong mostly awaiting coronary-artery bypass graft. Rosuvastatin 20mg daily was not shown to reduce atrial fibrillation, nor heart muscle damage. It did, as expected, reduce “bad” cholesterol and C-reactive protein, a marker of inflammation, compared to the inactive placebo.
Statins do have proven longer term benefits in reducing further damage to the coronary arteries and deaths from heart disease.
Why was this study needed?
Atrial fibrillation can occur in about 20% of people undergoing heart surgery and if not corrected is associated with poorer recovery and reduced ability to exercise.
Although a review of trials has suggested that statin therapy around the time of surgery might reduce some complications the studies were small and may have been susceptible to bias. The current trial aimed to compare use of rosuvastatin against placebo in a randomised controlled trial with a larger sample size.
What did this study do?
The STICS was a randomised controlled trial of 1,922 adults awaiting planned cardiac surgery, mostly coronary-artery bypass graft and some surgical aortic valve replacements. Adults were eligible if they had normal heart rhythms and were not taking medication for abnormal heart rhythms other than beta blockers.
Half were randomised to receive rosuvastatin 20 mg daily, and half to receive placebo daily for up to eight days before surgery (pre-operatively) and five days following surgery (post-operatively).
The researchers looked for atrial fibrillation, using continuous electrocardiographic monitoring, and for evidence of myocardial (heart muscle) injury, using standard blood tests, up to five days after surgery.
Adverse events, length of stay in hospital and intensive care and heart and liver function were also assessed.
What did it find?
- The rate of post-operative atrial fibrillation within five days was not reduced by rosuvastatin (21.1%) compared to placebo (20.5%), (odds ratio 1.04, 95% confidence interval [CI] 0.84 to 1.30).
- Troponin-I levels, which test for post-operative heart muscle injury, were no different in those that received rosuvastatin compared to those that received placebo (between group difference 1%, 95% CI 9 to 13).
- Higher plasma creatinine levels indicative of abnormal kidney function were seen with rosuvastatin compared to placebo. There was also a higher rate of acute kidney injury within two days of surgery for adults who received rosuvastatin (24.7%) compared to placebo (19.3%) p=0.005.
- There was no difference in length of hospital or intensive care stay or serious adverse events post-operatively between those that received rosuvastatin or placebo.
What does current guidance say on this issue?
European and US guidelines recommend taking perioperative statins to prevent atrial fibrillation and other in-hospital complications after cardiac surgery. However, these recommendations were based on small trials with limitations. Rosuvastatin was not specifically recommended over other statins.
NICE considers rosuvastatin 20 mg daily (the trial dose) a high intensity statin along with atorvastatin 20 to 80 mg daily and simvastatin 80 mg daily (the MHRA has a safety warning on simvastatin 80 mg due to muscle damage).
What are the implications?
For adults awaiting elective cardiac surgery, perioperative statin therapy with rosuvastatin 20 mg daily was not shown to reduce the risk of in-hospital atrial fibrillation or perioperative myocardial injury.
Acute kidney injury was more common in adults who received rosuvastatin than placebo although there was no difference in the number of other serious adverse events over the period of the study.
Citation and Funding
Zheng Z, Jayaram R, Jiang L, et al. Perioperative Rosuvastatin in Cardiac Surgery. N Engl J Med. 2016;374(18):1744-53.
This project was funded by the British Heart Foundation, the European Network for Translational Research in Atrial Fibrillation of the European Commission Seventh Framework Program, the Oxford Biomedical Research Centre, and the UK Medical Research Council and by a small unrestricted grant from AstraZeneca.
Bibliography
Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011;58(24):e123-210.
January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64(21):e1-76.
NHS Choices. Atrial fibrillation. London: Department of Health; updated 2015.
NICE. Cardiovascular disease: risk assessment and reduction, including lipid modification. CG181. London: National Institute of Health and Care Excellence; 2014.
NICE. Lipid-modifying drugs. KTT3. London: National Institute for Health and Care Excellence; 2016.
2020 ESC Guidelines for the management of atrial fibrillation. European Heart Journal, Volume 42, Issue 5, 1 February 2021, Pages 373–498,
Produced by the University of Southampton and Bazian on behalf of NIHR through the NIHR Dissemination Centre
NIHR Evidence is covered by the creative commons, CC-BY licence. Written content and infographics may be freely reproduced provided that suitable acknowledgement is made. Note, this licence excludes comments and images made by third parties, audiovisual content, and linked content on other websites.
